S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Unique BioPharma Opportunity for Accredited Investors (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Unique BioPharma Opportunity for Accredited Investors (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Unique BioPharma Opportunity for Accredited Investors (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Unique BioPharma Opportunity for Accredited Investors (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Unique BioPharma Opportunity for Accredited Investors (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Unique BioPharma Opportunity for Accredited Investors (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Unique BioPharma Opportunity for Accredited Investors (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Unique BioPharma Opportunity for Accredited Investors (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
NASDAQ:KNSA

Kiniksa Pharmaceuticals (KNSA) Stock Price, News & Analysis

$20.00
+0.28 (+1.42%)
(As of 02/23/2024 ET)
Today's Range
$19.74
$20.04
50-Day Range
$17.54
$20.55
52-Week Range
$10.29
$20.94
Volume
214,144 shs
Average Volume
394,771 shs
Market Capitalization
$1.41 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.50

Kiniksa Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
12.5% Upside
$22.50 Price Target
Short Interest
Bearish
3.92% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.91mentions of Kiniksa Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$1.24 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.54) to ($0.11) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.71 out of 5 stars

Medical Sector

670th out of 941 stocks

Biotechnology Industry

11th out of 24 stocks


KNSA stock logo

About Kiniksa Pharmaceuticals Stock (NASDAQ:KNSA)

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that completed Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

KNSA Stock Price History

KNSA Stock News Headlines

Discover Lexagene - Open to Accredited Investors Only
Get access to significant growth potential in a rapidly scaling biopharma market
Discover Lexagene - Open to Accredited Investors Only
Get access to significant growth potential in a rapidly scaling biopharma market
GSK (GSK) Misses Q4 Earnings Estimates
Kiniksa Pharmaceuticals Provides Corporate Update
See More Headlines
Receive KNSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiniksa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2021
Today
2/23/2024
Next Earnings (Confirmed)
2/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KNSA
Fax
N/A
Employees
220
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$22.50
High Stock Price Target
$25.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+12.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$183.36 million
Pretax Margin
-4.93%

Debt

Sales & Book Value

Annual Sales
$220.18 million
Cash Flow
$2.67 per share
Book Value
$5.68 per share

Miscellaneous

Free Float
32,194,000
Market Cap
$1.41 billion
Optionable
Optionable
Beta
0.24
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Sanj K. Patel (Age 54)
    CEO & Chairman of the Board
    Comp: $1.44M
  • Mr. Eben Tessari (Age 42)
    Senior VP & COO
    Comp: $643.75k
  • Dr. John F. Paolini (Age 59)
    Senior VP & Chief Medical Officer
    Comp: $753.7k
  • Mr. Mark Ragosa C.F.A. (Age 49)
    Senior VP & CFO
  • Mr. Michael R. Megna CPA (Age 53)
    Chief Accounting Officer & Group VP of Finance
  • Ms. Mei Jang
    Senior VP of Technical Operations
  • Rachel Frank
    Associate Director of Investor Relations
  • Mr. Chad Morin
    SVP, Chief Compliance Officer & Head of Quality
  • Ms. Melissa Manno
    Senior VP & Chief Human Resources Officer
  • Mr. Carsten Boess (Age 57)
    Executive Vice President of Corporate Affairs














KNSA Stock Analysis - Frequently Asked Questions

Should I buy or sell Kiniksa Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KNSA shares.
View KNSA analyst ratings
or view top-rated stocks.

What is Kiniksa Pharmaceuticals' stock price target for 2024?

2 Wall Street research analysts have issued 12 month price objectives for Kiniksa Pharmaceuticals' stock. Their KNSA share price targets range from $20.00 to $25.00. On average, they predict the company's share price to reach $22.50 in the next year. This suggests a possible upside of 12.5% from the stock's current price.
View analysts price targets for KNSA
or view top-rated stocks among Wall Street analysts.

How have KNSA shares performed in 2024?

Kiniksa Pharmaceuticals' stock was trading at $17.54 at the start of the year. Since then, KNSA stock has increased by 14.0% and is now trading at $20.00.
View the best growth stocks for 2024 here
.

Are investors shorting Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals saw a increase in short interest in January. As of January 31st, there was short interest totaling 2,760,000 shares, an increase of 5.7% from the January 15th total of 2,610,000 shares. Based on an average daily trading volume, of 448,200 shares, the short-interest ratio is currently 6.2 days.
View Kiniksa Pharmaceuticals' Short Interest
.

When is Kiniksa Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our KNSA earnings forecast
.

How can I listen to Kiniksa Pharmaceuticals' earnings call?

Kiniksa Pharmaceuticals will be holding an earnings conference call on Wednesday, February 28th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Kiniksa Pharmaceuticals' earnings last quarter?

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) released its earnings results on Monday, November, 1st. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.21. The firm had revenue of $12.10 million for the quarter, compared to the consensus estimate of $9.92 million. Kiniksa Pharmaceuticals had a negative trailing twelve-month return on equity of 5.78% and a negative net margin of 2.80%.

What ETFs hold Kiniksa Pharmaceuticals' stock?

ETFs with the largest weight of Kiniksa Pharmaceuticals (NASDAQ:KNSA) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP).ALPS Medical Breakthroughs ETF (SBIO).

What is Sanj K. Patel's approval rating as Kiniksa Pharmaceuticals' CEO?

1 employees have rated Kiniksa Pharmaceuticals Chief Executive Officer Sanj K. Patel on Glassdoor.com. Sanj K. Patel has an approval rating of 100% among the company's employees. This puts Sanj K. Patel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Kiniksa Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Pfizer (PFE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Dicerna Pharmaceuticals (DRNA), Vaxart (VXRT) and Advanced Micro Devices (AMD).

When did Kiniksa Pharmaceuticals IPO?

(KNSA) raised $126 million in an initial public offering on Thursday, May 24th 2018. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Kiniksa Pharmaceuticals' major shareholders?

Kiniksa Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.22%), Rubric Capital Management LP (4.13%), Goldman Sachs Group Inc. (1.29%), Granahan Investment Management LLC (1.03%), Parkman Healthcare Partners LLC (0.88%) and Altitude Crest Partners Inc. (0.65%). Insiders that own company stock include Barry D Quart, John F Paolini, Mark Ragosa and Michael R Megna.
View institutional ownership trends
.

How do I buy shares of Kiniksa Pharmaceuticals?

Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KNSA) was last updated on 2/24/2024 by MarketBeat.com Staff